A recent study demonstrated that targeting tumor cell-intrinsic CTRP6 with a biomimetic codelivery system synergistically enhanced ferroptosis and immune activation, thereby improving the efficacy of anti-PD-L1 immunotherapy in lung cancer [20]. This evidence concerns the gene C1QTNF6 and lung carcinoma.